.After raising $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on everyone market.The Eli Lilly-partnered biotech expect to list on the Nasdaq under the icon “BIOA,” depending on to documentations submitted with the Securities and also Substitution Payment. The firm has certainly not publicly shared an assumed financial quantity for the offering.The clinical-stage company proclaims lead candidate azelaprag, an orally supplied little particle slated to enter phase 2 screening in combination with semaglutide– marketed through Novo Nordisk under brand Wegovy for fat burning– in the very first one-half of upcoming year. Semaglutide is actually likewise marketed as Ozempic and also Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually created to blend properly with GLP-1 drugs, boosting effective weight loss while maintaining muscle mass. The investigational medicine was discovered to become well-tolerated one of 265 individuals around 8 phase 1 tests, depending on to BioAge.Recently, BioAge amassed the assistance of Lilly to manage a test mixing azelaprag along with the Big Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetic issues as Mounjaro and Zepbound for weight reduction. The companions are actually presently administering a stage 2 trial of azelaprag as well as tirzepatide, with topline results anticipated in the third one-fourth of 2025.The biotech is actually also considering a the hormone insulin sensitiveness proof-of-concept test assessing azelaprag as a monotherapy in the 1st one-half of next year to assist possible sign expansion.
On top of that, the business intends to inquire the FDA for approval in the 2nd half of 2025 to release individual screening for an NLRP3 inhibitor targeting metabolic illness and also neuroinflammation.BioAge’s foreseed move to the general public market follows a mild uptick in considered biotech IPOs coming from Bicara Therapies as well as Zenas Biopharma. Zooming out, the current IPO yard is actually a “combined picture,” along with high-quality companies still debuting on everyone markets, merely in lessened amounts, depending on to PitchBook.